PUBLICATIONS
研究論文
-
21. Li H#, (Li CW#), Li X, Ding Q, Guo L, Liu S, Liu C, Lai CC, Hsu JM, Dong Q, Xia W, Hsu JL, Yamaguchi H, Du Y, Lai YJ, Sun X, Koller PB, Ye Q, Hung MC*, # Contributed equally MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology 156(6), 1849-1861.e13 (2019-05) [JCR] [WOS] -
22. Yang Y, Hsu JM, Sun L, Chan LC, (Li CW), Hsu JL, Wei Y, Xia W, Hou J, Qiu Y, Hung MC* Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell research 29(1), 83-86 (2019-01) [JCR] [WOS] -
23. Han Y, (Li CW*), Hsu JM, Hsu JL, Chan LC, Tan X, He GJ Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer. American journal of cancer research 9(4), 800-815 (2019) [JCR] [WOS] -
24. Han Y, Chen MK, Wang HL, Hsu JL, (Li CW), Chu YY, Liu CX, Nie L, Chan LC, Yam C, Wang SC, He GJ, Hortobagyi GN, Tan XD, Hung MC* Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. American journal of cancer research 9(3), 608-618 (2019) [JCR] [WOS] -
25. (Li CW), Lai YJ, Hsu JL, Hung MC* Activation of phagocytosis by immune checkpoint blockade. Frontiers of medicine 12(4), 473-480 (2018) [JCR] [WOS] -
26. Ding Q, Wang Y, Zuo Z, Gong Y, Krishnamurthy S, (Li CW), Lai YJ, Wei W, Wang J, Manyam GC, Diao L, Zhang X, Lin F, Symmans WF, Sun L, Liu CG, Liu X, Debeb BG, Ueno NT, Harano K, Alvarez RH, Wu Y, Cristofanilli M, Huo L* Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Human pathology 77, 121-129 (2018) [JCR] [WOS] -
27. Shao B, (Li CW), Lim SO, Sun L, Lai YJ, Hou J, Liu C, Chang CW, Qiu Y, Hsu JM, Chan LC, Zha Z, Li H, Hung MC* Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. American journal of cancer research 8(9), 1837-1846 (2018) [JCR] [WOS] -
28. (Li CW#), Lim SO#, Chung EM, Kim YS, Park AH, Yao J, Cha JH, Xia W, Chan LC, Kim T, Chang SS, Lee HH, Chou CK, Liu YL, Yeh HC, Perillo EP, Dunn AK, Kuo CW, Khoo KH, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Huang TH, Sahin AA, Hortobagyi GN, Yoo SS, Hung MC*, # contributed equally Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer cell 33(2), 187-201.e10 (2018) [JCR] [WOS] -
29. Yang Y, (Li CW), Chan LC, Wei Y, Hsu JM, Xia W, Cha JH, Hou J, Hsu JL, Sun L, Hung MC* Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell research 28(8), 862-864 (2018) [JCR] [WOS] -
30. Sun LL, Yang RY, (Li CW), Chen MK, Shao B, Hsu JM, Chan LC, Yang Y, Hsu JL, Lai YJ, Hung MC* Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. American journal of cancer research 8(7), 1307-1316 (2018) [JCR] [WOS]
| Record 21 to 30, total of 58 records |